Quarterly report · Q3
7446.TEDINET S100RLXQ
Period2022-10-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.9bn | 2022-10-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥37.3bn | 2021-10-01 → 2022-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.9bn | 2021-10-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥659m | 2022-10-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥763m | 2021-10-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥708m | 2022-10-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-10-01 → 2022-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥814m | 2021-10-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥707m | 2022-10-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥786m | 2021-10-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥499m | 2022-10-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥658m | 2021-10-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥539m | 2021-10-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥507m | 2022-10-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥559m | 2021-10-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥17.8bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥17.5bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥15.0bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.5bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥10.8bn | at 2022-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥7.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.6bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.4bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥553.84 | 2022-10-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.63 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥728.76 | 2021-10-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥596.99 | 2021-10-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥185.03 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.3% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.7% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.2% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-10-01 → 2023-06-30 | ¥313m |
| Otherother segments | revenue external | 2022-10-01 → 2023-06-30 | ¥313m |
| jpcrp040300-q3r_E02810-000Foodreportable segment | revenue | 2022-10-01 → 2023-06-30 | ¥2.5bn |
| jpcrp040300-q3r_E02810-000Foodreportable segment | revenue external | 2022-10-01 → 2023-06-30 | ¥2.5bn |
| jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segment | revenue | 2022-10-01 → 2023-06-30 | ¥13.5bn |
| jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segment | revenue external | 2022-10-01 → 2023-06-30 | ¥13.5bn |
| jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segment | revenue | 2022-10-01 → 2023-06-30 | ¥10.6bn |
| jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segment | revenue external | 2022-10-01 → 2023-06-30 | ¥10.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-10-01 → 2023-06-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-10-01 → 2023-06-30 | ¥26.9bn |
| Otherother segments | revenue | 2021-10-01 → 2022-06-30 | ¥318m |
| Otherother segments | revenue external | 2021-10-01 → 2022-06-30 | ¥318m |
| jpcrp040300-q3r_E02810-000Foodreportable segment | revenue | 2021-10-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q3r_E02810-000Foodreportable segment | revenue external | 2021-10-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segment | revenue | 2021-10-01 → 2022-06-30 | ¥13.8bn |
| jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segment | revenue external | 2021-10-01 → 2022-06-30 | ¥13.8bn |
| jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segment | revenue | 2021-10-01 → 2022-06-30 | ¥11.4bn |
| jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segment | revenue external | 2021-10-01 → 2022-06-30 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-10-01 → 2022-06-30 | ¥27.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-10-01 → 2022-06-30 | ¥27.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 382
| Item | Context | Value | Unit |
|---|---|---|---|
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)１単元（100株）未満の株式 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東北化学薬品㈱ | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)青森県弘前市大字神田１-３-１ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |